Stanford radiation oncologist prostate cancer expert Dr. Patrick Swift presents on the new advances on prostate cancer and its treatment. Watch the recording HERE
URO Today has published a collection of videos from the APCC 2019 conference. This informative collection of 60 short videos cover a wide range of prostate cancer topics. You can view the video collection on URO Today HERE
Food and Drug Administration (FDA) approved
Read the entire article on pcf.org HERE
Dr. Andrei Iagaru, Professor of Radiology and Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford presented to our group about Nuclear Medicine at Stanford University and Updates on Clinical/Research Activities in Prostate Cancer on March 7, 2019.
Access the recording and presentation slides from the links below:
From Dr. Fabio’s blog post:
Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available? How do they compare? What are the parameters for successful imaging?
We are proud to have contributed to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published – representing the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview of PET/CT Imaging for Prostate Cancer follow for your review. We hope you find this review useful.
Read the entire article on drfabio.com HERE
Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine.
Note that this article mentions C-11 acetate briefly but does not cover it. Phoenix Molecular Imaging is not shown on the map of imaging centers. Also, the study does not examine the significance of PSA doubling time, whereas it has been reported that short doubling time enhances detection with C11-Acetate even at very low PSA.
Read the entire article on sciencedirect.com HERE
Opinion Article by Charles Maack
The information in this article is a lengthy read, but for men moved to androgen deprivation therapy the information is extremely important to be aware since everything explained may be involved in their well-being.
Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of:
- a LHRH/GnRH agonist or antagonist to shut down testicular testosterone production
- an antiandrogen to block testosterone access to the cancer cell nucleus
- a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT
Read the entire article on oncogen.org HERE
As many as 40% of newly diagnosed PCa patients have unifocal disease, that is, just one focus of cancer. But that still leaves 60-80% of patients with multifocal PCa. Without evidence to the contrary, multiple foci in the same gland were thought to be biologically homogeneous, that is, identical to each other.
Then, along came the tools to analyze PCa at the molecular level, bringing new knowledge of the biology of PCa.
Read about this by clicking here.
Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Learn more about these interesting findings by clicking HERE.
The U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Enzalutamide was previously approved only for patients with metastatic CRPC. Prior to this past February – when the FDA also approved apalutamide (Erleada) for non-metastatic CRPC – there were no FDA-approved treatments for these men.
Read more on PCF.org HERE